Nevertheless, using DIO mouse models, we show that EA treatment for 2 weeks already nearly reversed metabolic abnormalities caused by long-term feeding with HFD in obese mice consistent with expected metabolic effects of GLP-1 and PYY, thus providing evidence that this agent may have substantial therapeutic potential for T2D. This evidence concerns the gene PYY and type 2 diabetes mellitus.